Drug Trial Radar · NCT01852461
Perfusion Index Variability in Respiratory Distress Syndrome
Last checked: Nov 19, 2026Latest source record: May 13, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
92
Actual
Start
Aug 2011
Primary completion
Dec 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- Dr. Sami Ulus Children's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 13, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 day, up to 3 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Perfusion index may vary according to type of surfactant during the treatment of respiratory distress syndrome.
Conditions
- Poor Peripheral Perfusion
Interventions
BeractantDrug
Beractant;both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
Poractant alfaDrug
porcine lung extract, initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
Primary outcomes
What the sponsor says the trial is designed to measure.
- perfusion indexTime frame: 1 week
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.